Enzyme replacement therapy in Gaucher's disease: preliminary clinical trial of a new enzyme preparation.
A patient with far-advanced adult type Gaucher's disease was treated with solubilized, highly purified placental glucocerebrosidase administered after entrapment in human erythrocytes or by direct intravenous injection. In some instances the enzyme-containing erythrocytes were coated with gamma globulin. No toxic side effects were observed after enzyme infusion. There were suggestive, but not conclusive, findings that enzyme infusion may have been beneficial. After therapy, there was a decrease in transfusion requirement, some improvement of liver function, possible decrease in liver size, and relief of subjective symptoms. Erythrocyte and plasma glucocerebroside levels were unchanged during therapy, but there was a possibly significant decrease in leukocyte and platelet levels of the glycolipid. No changes occurred in serum acid phosphatase or angiotensin-converting enzyme activity.
D000135:Acid Phosphatase / Q000097:blood; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001772:Blood Cell Count; D005260:Female; D005776:Gaucher Disease / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D005959:Glucosidases / Q000627:therapeutic use*; D005962:Glucosylceramidase / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D006801:Humans; D008099:Liver / Q000000981:diagnostic imaging / Q000473:pathology; D009929:Organ Size; D007703:Peptidyl-Dipeptidase A / Q000097:blood; D010920:Placenta / Q000201:enzymology; D011877:Radionuclide Imaging; D013997:Time Factors
D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000135:Acid Phosphatase; D005959:Glucosidases; D005962:Glucosylceramidase; D007703:Peptidyl-Dipeptidase A